A systematic review of the cost–effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C

References

• National Institute for Health and Clinical Excellence. Peginterferon-α and ribavirin for the treatment of mild chronic hepatitis C. NICE Technology Appraisal Guidance. NICE, London, UK 1–31 (2006).
   Google Scholar
• Hutchinson SJ, Bird SM, Goldberg DJ. Review of models used to predict the future numbers of individuals with severe hepatitis C disease: therapeutic and cost implications. Expert Rev. Pharmacoeconomics Outcomes Res.6(6), 627–639 (2006).
   Google Scholar
• Poynard T, McHutchison J, Goodman Z et al. Is an “a la carte” combination interferon α-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. [Erratum appears in Hepatology32(2), 446 (2000)]. Hepatology31(1), 211–218 (2000).
   Google Scholar
• Carithers RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon α-2b trials (structured abstract). Hepatology26(3 Suppl. 1), S83–S88 (1997).
   PubMed Web of Science ®Google Scholar
• Myers RP, Regimbeau C, Thevenot T et al. Interferon for interferon naive patients with chronic hepatitis C. In: The Cochrane Database of Systematic Reviews: Reviews. John Wiley & Sons, Ltd, Chichester, UK 2 (2002).
   Google Scholar
• Manns MP, McHutchison JG, Gordon SC et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized tria [see comment]. Lancet358(9286), 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection [see comment]. N. Engl. J. Med.347(13), 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Interferon-α (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. Technology Appraisal. NICE, London, UK 1–38 (2004).
   Google Scholar
• National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002. Hepatology36(5 Suppl. 1), 20 (2002).
   Google Scholar
• Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C [see comment] [erratum appears in Hepatology40(1), 269 (2004)]. Hepatology39(4), 1147–1171 (2004).
   Google Scholar
• Joint Formulary Committee. British National Formulary 54. London: British Medical Association and Royal Pharmaceutical Society of Great Britain 1–974 (2007).
   Google Scholar
• Shepherd J, Brodin H, Cave C et al. Pegylated interferon-α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol. Assess.8(39), 1–125 (2004).
   Web of Science ®Google Scholar
• Shepherd J, Jones J, Hartwell D et al. Interferon-α (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol. Assess.11(11), 1–224 (2007).
   PubMed Web of Science ®Google Scholar
• Bennett WG, Inoue Y, Beck JR et al. Estimates of the cost–effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann. Intern. Med.127(10), 855–865 (1997).
   PubMed Web of Science ®Google Scholar
• Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA280(24), 2088–2093 (1998).
   PubMed Web of Science ®Google Scholar
• Grieve R, Roberts J, Wright M et al. Cost–effectiveness of interferon-α or peginterferon-α with ribavirin for histologically mild chronic hepatitis C. Gut55(9), 1332–1338 (2006).
   PubMed Web of Science ®Google Scholar
• Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost–effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. J. Am. Med. Assoc.290(2), 228–237 (2003).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Brodin HFT, Cave CB et al. Clinical- and cost–effectiveness of pegylated interferon α in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int. J. Technol. Assess. Health Care21(1), 47–54 (2005).
   PubMed Web of Science ®Google Scholar
• Simon K, Gladysz A, Rotter K et al. Cost–effectiveness of replacing recombinated interferon α-2b with its pegylated form in combination with ribavirin for the therapy of chronic HCV infection in Poland. Adv. Clin. Exp. Med.15(3), 453–462 (2006).
   Google Scholar
• Buti M, Medina M, Casado MA et al. A cost–effectiveness analysis of peginterferon α-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment. Pharmacol. Ther.17(5), 687–694 (2003).
   PubMed Web of Science ®Google Scholar
• Bernfort L, Sennfalt K, Reichard O. Cost–effectiveness of peginterferon α-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand. J. Infect. Dis.38(6–7), 497–505 (2006).
   PubMed Web of Science ®Google Scholar
• Wright M, Forton D, Main J et al. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J. Viral Hepat.12(1), 58–66 (2005).
   Google Scholar
• Wright M, Grieve R, Roberts J et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomized controlled trial and economic evaluation. Health Technol. Assess.10(21), 1–113.
   Google Scholar
• Lin WA, Tarn YH, Tang SL. Cost–utility analysis of different peg-interferon-α-2b plus ribavirin treatment strategies as initial therapy for naive Chinese patients with chronic hepatitis C. Aliment. Pharmacol. Ther.24(10), 1483–1493 (2006).
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Rossol S et al. Cost–effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C [see comment]. Gut52(3), 425–432 (2003).
   PubMed Web of Science ®Google Scholar
• Wong JB, Nevens F. Cost–effectiveness of peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol. Belg.65(2), 110–111 (2002).
   PubMed Web of Science ®Google Scholar
• Wong JB, Davis GL, McHutchison JG et al. Economic and clinical effects of evaluating rapid viral response to peginterferon α-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am. J. Gastroenterol.98(11), 2354–2362 (2003).
   PubMedGoogle Scholar
• Davis GL, Wong JB, McHutchison JG et al. Early virologic response to treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C. Hepatology38(3), 645–652 (2003).
   PubMed Web of Science ®Google Scholar
• Sweeting MJ, De AD, Neal KR et al. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J. Clin. Epidemiol.59(2), 144–152 (2006).
   Google Scholar
• Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients [see comment]. Gastroenterology112(2), 463–472 (1997).
   PubMed Web of Science ®Google Scholar
• Lee SD, Yu ML, Cheng PN et al. Comparison of a 6-month course peginterferon α-2b plus ribavirin and interferon α-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J. Viral Hepat.12(3), 283–291 (2005).
   PubMed Web of Science ®Google Scholar
• Yu ML, Dai CY, Lin ZY et al. A randomized trial of 24- vs. 48-week courses of PEG interferon α-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int.26(1), 73–81 (2006).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon α-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol.40(6), 993–999 (2004).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol.44(1), 97–103 (2006).
   PubMed Web of Science ®Google Scholar
• Mangia A, Santoro R, Minerva N et al. Peginterferon α-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med.352(25), 2609–2617 (2005).
   PubMed Web of Science ®Google Scholar
• Muir AJ, Bornstein JD, Killenberg PG et al. Peginterferon α-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites [see comment] [erratum appears in N. Engl. J. Med.351(12), 1268 (2004)]. N. Engl. J. Med.350(22), 2265–2271 (2004).
   Google Scholar
• McHutchison JG, Gordon SC, Schiff ER et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med.339(21), 1485–1492 (1998).
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS et al. Randomized trial of interferon-α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) [see comment]. Lancet352(9138), 1426–1432 (1998).
   PubMed Web of Science ®Google Scholar
• Barbaro G, Di LG, Soldini M et al. Evaluation of long-term efficacy of interferon α-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin–Interferon in Chronic Hepatitis Italian Group Investigators [see comment]. J. Hepatol.33(3), 448–455 (2000).
   PubMedGoogle Scholar
• Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon-α-2b to interferon-α-2b as initial treatment for chronic hepatitis C. Hepatology34(2), 395–403 (2001).
   PubMed Web of Science ®Google Scholar
• Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am. J. Epidemiol.156(8), 761–773 (2002).
   PubMed Web of Science ®Google Scholar
• Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology36(5 Suppl. 1), S145–S151 (2002).
   Google Scholar
• Wong JB, Poynard T, Ling MH et al. Cost–effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group [see comment]. Am. J. Gastroenterol.95(6), 1524–1530 (2000).
   PubMedGoogle Scholar
• Sennfalt K, Reichard O, Hultkrantz R et al. Cost–effectiveness of interferon α-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand. J. Gastroenterol.36(8), 870–876 (2001).
   PubMedGoogle Scholar
• Wright M, Goldin R, Fabre A et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut52(4), 574–579 (2003).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon α and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol. Assess.4, 33 (2000).
   Google Scholar
• Siebert U, Ravens-Sieberer U, Greiner W, et al. Patient-based health-related quality of life in different health stages of chronic hepatitis C. Hepatology34, 222A (2001).
   Google Scholar
• Philips Z, Ginnelly L, Sculpher M et al. Review of guidelines for good practice in decision-analytic modeling in health technology assessment. Health Technol. Assess.8(36), iii–iiv (2004).
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon-α-2b vs standard interferon-α-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial [see comment]. JAMA292(23), 2839–2848 (2004).
   PubMed Web of Science ®Google Scholar
• Laguno M, Murillas J, Blanco JL et al. Peginterferon-α-2b plus ribavirin compared with interferon-α-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS18(13), F27–F36 (2004).
   Google Scholar
• Poynard T. HCV-RNA negativity after 12 weeks of therapy is the best predictor of sustained viral response (SVR) in the retreatment of previous interferon α/ribavirin nonresponders (NR): results from the EPIC3 Program. Presented at: the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, USA, 11–15 November 2006 (Poster 1123).
   Google Scholar
• Poynard T, Mathurin P, Lai CL et al. A comparison of fibrosis progression in chronic liver diseases [see comment]. J. Hepatol.38(3), 257–265 (2003).
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, Charlotte F et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol.34(5), 730–739 (2001).
   PubMed Web of Science ®Google Scholar
• Ryder SD, Irving WL, Jones DA et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study [see comment]. Gut53(3), 451–455 (2004).
   PubMed Web of Science ®Google Scholar
• Department of Health. Hepatitis C Action plan for England. 2004. London, Department of Health. Crown Copyright 1–16 (2004).
   Google Scholar
• Mangia A, Santoro R, Minerva N et al. Peginterferon α-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med.352(25), 2609–2617 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras F, Nevarez-Sida A, Constantino-Casas P, Abud-Bastida F, Garduno-Espinosa J. Cost–effectiveness of chronic hepatitis C treatment with thymosin α-1. Arch. Med. Res.37(5), 663–673 (2006).
   Google Scholar